Search Results

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates for the treatment of solid tumors.

Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.

Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.

Innovent Biologics, Inc. announced the signing of a non-exclusive, target-specific license agreement with Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates with best-in-class therapeutic index.

Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline

Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V., a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates, announced the signing of a license and option agreement.

Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies.

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company.

In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.

Synaffix B.V., a biotechnology company enabling antibody-drug conjugates with best-in-class therapeutic index, announces that it has won the “Best ADC Platform Technology” category at the 2020 World ADC Awards ceremony.